nach oben

Rechtsmedizin

Erschienen in:

01.08.2012 | CME Zertifizierte Fortbildung

Synthetische Cannabinoide

Forensische Relevanz und Interpretation analytischer Befunde

verfasst von: PD Dr. rer. nat. V. Auwärter, S. Kneisel, M. Hutter, A. Thierauf

Erschienen in: Rechtsmedizin | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den vergangenen Jahren erreichte weltweit eine wahre Flut von neuen, auch als „legal highs“ bezeichneten Drogenprodukten den Markt. Während in einigen Teilen der Welt eher die amphetaminartigen Stimulanzien dominieren, stellen in Deutschland bisher die synthetischen Cannabinoide das größere Problem dar. Die hohe Dynamik, die durch rasche Aufnahme neuer Substanzen in die Anlagen des Betäubungsmittelgesetzes und den Ersatz auf Herstellerseite durch chemisch-strukturell leicht veränderte, neue Substanzen zustande kommt, stellt sowohl die Kriminaltechnik als auch die Toxikologie vor immense Herausforderungen.

Mechoulam R, Gaoni Y (1965) A total synthesis of dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3275PubMedCrossRef

Matsuda LA, Lolait SJ, Brownstein MJ et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564PubMedCrossRef

Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65PubMedCrossRef

Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17:179–202PubMedCrossRef

Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45–60PubMedCrossRef

Thakur GA, Tichkule R, Bajaj S, Makriyannis A (2009) Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 19:1647–1673PubMedCrossRef

Christensen R, Kristensen PK, Bartels EM et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–1713PubMedCrossRef

Auwärter V, Dresen S, Weinmann W et al (2009) „Spice“ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMedCrossRef

Werse B, Morgenstern C (2011) Abschlussbericht – Online-Befragung zum Thema „Legal Highs“. Centre for Drug Research, Goethe-Universität, Frankfurt a. M.

10.

Pabst A, Piontek D, Kraus L, Müller S (2010) Substanzkonsum und substanzbezogene Störungen. Ergebnisse des Epidemiologischen Suchtsurveys 2009. Sucht 56:327–336

11.

Werse B, Müller O, Schell C, Morgenstern C (2011) Jahresbericht MoSyD. Drogentrends in Frankfurt am Main 2010. Centre for Drug Research, Goethe-Universität, Frankfurt a. M.

12.

Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35:1803–1810PubMedCrossRef

13.

Howlett AC, Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532–538PubMed

14.

Caulfield MP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231–232PubMedCrossRef

15.

Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89:3825–3829PubMedCrossRef

16.

Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedCrossRef

17.

Johnson DE, Heald SL, Dally RD et al (1993) Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot Essent Fatty Acids 48:429–437PubMedCrossRef

18.

Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90PubMedCrossRef

19.

Mascia MS, Obinu MC, Ledent C et al (1999) Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol 383:R1–2PubMedCrossRef

20.

Fernandez-Ruiz J, Berrendero F, Hernandez ML et al (2000) The endogenous cannabinoid system and brain development. Trends Neurosci 23:14–20PubMedCrossRef

21.

Johnson MR, Rice KC, Howlett A et al (1992) The cannabinoid receptor – pharmacologic identification, anatomical localization and cloning. NIDA Res Monogr 119:86–90PubMed

22.

Pavlopoulos S, Thakur GA, Nikas SP et al (2006) Cannabinoid receptors as therapeutic targets. Curr Pharm Des 12:1751–1769PubMedCrossRef

23.

Ishac EJ, Jiang L, Lake KD et al (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023–2028PubMedCrossRef

24.

Kathmann M, Bauer U, Schlicker E et al (1999) Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 359:466–470PubMedCrossRef

25.

Nakazi M, Bauer U, Nickel T et al (2000) Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 361:19–24PubMedCrossRef

26.

Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322–4334PubMed

27.

Szabo B, Müller T, Koch H (1999) Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73:1084–1089PubMedCrossRef

28.

Felder CC, Joyce KE, Briley EM et al (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443–450PubMed

29.

Lambert DM, Di Marzo V (1999) The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6:757–773PubMed

30.

Wiley JL, Martin BR (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121:57–63PubMedCrossRef

31.

Forrester MB, Kleinschmidt K, Schwarz E, Young A (2011) Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 30:351–358PubMedCrossRef

32.

Hoyte CO, Jacob J, Monte AA et al (2012) A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med, DOI 10.1016/j.annemergmed.2012.03.007

33.

Pant S, Deshmukh A, Dholaria B et al (2012) Spicy seizure. Am J Med Sci 344:67–68PubMedCrossRef

34.

Schneir AB, Baumbacher T (2012) Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 8:62–64PubMedCrossRef

35.

Aung MM, Griffin G, Huffman JW et al (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 60:133–140PubMedCrossRef

36.

Compton DR, Rice KC, De Costa BR et al (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218–226PubMed

37.

D’Ambra TE, Estep KG, Bell MR et al (1992) Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35:124–135CrossRef

38.

Deng H, Gifford AN, Zvonok AM et al (2005) Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J Med Chem 48:6386–6392PubMedCrossRef

39.

Frost JM, Dart MJ, Tietje KR et al (2010) Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem 53:295–315PubMedCrossRef

40.

Huffman JW, Mabon R, Wu MJ et al (2003) 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 11:539–549PubMedCrossRef

41.

Huffman JW, Padgett LW (2005) Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 12:1395–1411PubMedCrossRef

42.

Huffman JW, Padgett LW, Isherwood ML et al (2006) 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett 16:5432–5435PubMedCrossRef

43.

Huffman JW, Szklennik PV, Almond A et al (2005) 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett 15:4110–4113PubMedCrossRef

44.

Makriyannis A, Deng H (2001) Cannabimimetic indole derivatives, W.I.P. Organization (Patent)

45.

Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989–999PubMed

46.

Mir A, Obafemi A, Young A, Kane C(2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:e1622–e1627PubMedCrossRef

47.

Schmid K, Niederhoffer N, Szabo B (2003) Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch Pharmacol 368:301–308PubMedCrossRef

48.

Advisory Council on the Misuse of Drugs (ACMD) (2009) Consideration of the major cannabinoid agonists. Home Office, London

49.

Howlett AC, Barth F, Bonner TI et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202PubMedCrossRef

50.

Thakur GA, Nikas SP, Makriyannis A (2005) CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5:631–640PubMedCrossRef

51.

Huffman J (2009) Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions. In: Reggio PH (Hrsg) The cannabinoid receptors. Humana, New York

52.

Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of „Spice“ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585–593PubMedCrossRef

53.

Teske J, Weller JP Fieguth A et al (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:2659–2663PubMedCrossRef

54.

Dresen S, Kneisel S, Weinmann W et al (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 46:163–171PubMedCrossRef

55.

Kacinko SL, Xu A, Homan JW et al (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol 35:386–393PubMedCrossRef

56.

Ammann J, Mc Laren JM, Gerostamoulos D, Beyer J et al (2012) Detection and quantification of new designer drugs in human blood: part 1 – synthetic cannabinoids. J Anal Toxicol 36:372–380PubMedCrossRef

57.

Poklis JL, Amira D, Wise LE et al (2012) Detection and disposition of JWH-018 and JWH-073 in mice after exposure to „Magic Gold“ smoke. Forensic Sci Int. DOI 10.1016/j.forsciint.2012.02.003

58.

Shanks KG, Dahn T, Terrell AR (2012) Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 36:145–152PubMedCrossRef

59.

Kneisel S, Auwärter V (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom. DOI 10.1002/jms.3020

60.

Coulter C, Garnier M, Moore C (2011) Synthetic cannabinoids in oral fluid. J Anal Toxicol 35:424–430PubMedCrossRef

61.

Salomone A, Gerace E, D’Urso F et al (2012) Simultaneous analysis of several synthetic cannabinoids, THC, CBD and CBN, in hair by ultra-high performance liquid chromatography tandem mass spectrometry. Method validation and application to real samples. J Mass Spectrom 47:604–610PubMedCrossRef

62.

Hutter M, Kneisel S, Auwärter V, Neukamm MA (2012) Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (in press)

63.

Möller I, Wintermeyer A, Bender K et al (2011) Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 3:609–620PubMedCrossRef

64.

Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‚herbal mixtures‘ using LC-MS/MS techniques. J Mass Spectrom 47:54–65PubMedCrossRef

65.

Moran CL, Le VH, Chimalakonda KC et al (2011) Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83:4228–4236PubMedCrossRef

66.

Johansson E, Halldin MM (1989) Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13:218–223PubMed

67.

Fraser AD, Worth D (2003) Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Forensic Sci Int 133:26–31PubMedCrossRef

Titel: Synthetische Cannabinoide
Forensische Relevanz und Interpretation analytischer Befunde
verfasst von: PD Dr. rer. nat. V. Auwärter
S. Kneisel
M. Hutter
A. Thierauf
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: Rechtsmedizin / Ausgabe 4/2012
Print ISSN: 0937-9819
Elektronische ISSN: 1434-5196
DOI: https://doi.org/10.1007/s00194-012-0810-4

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Synthetische Cannabinoide

Forensische Relevanz und Interpretation analytischer Befunde

Zusammenfassung

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Epipleurales Hämatom

Mit Geschichtsbewusstsein in die Zukunft

Letale Doxepinintoxikation

Maximale Blutalkoholkonzentration nach forciertem Konsum von alkoholfreiem Bier

Mitteilungen der Deutschen Gesellschaft für Rechtsmedizin

Vortäuschung einer Schussverletzung durch einen entzündlich-tumorös bedingten Hautdefekt

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie